|
|
Article: Immunicon Corporation Announces Presentation of Data on Circulating Tumor Cells versus Serum Tumor Markers in Metastatic Breast Cancer at the 2005 American Association of Clinical Oncology (ASCO) Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- May 17, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
HUNTINGDON VALLEY, Pa., May 17 /PRNewswire-FirstCall/ -- Immunicon Corporation , a development-stage company developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer, announced the presentation of further data from its clinical trial in metastatic breast cancer and the significance of circulating tumor cells (CTCs) versus serum tumor markers. The abstract entitled: "Circulating tumor cells -- not serum tumor markers -- predict survival in metastatic breast cancer," Abstract 9516, was presented on Tuesday, May 17, 2005, from 8:00 a.m. - 12:00 Noon ET, by Alison T. Stopeck, M.D., ...